SCHEMBL19008534

SCHEMBL19008534

CCCC(=O)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 4/20 0.42
HDAC2 Q92769 4/20 0.42
HDAC6 Q9UBN7 2/20 0.42
CA14 Q9ULX7 3/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA7 P43166 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
ALDH1A1 P00352 2/20 0.34
TP53 P04637 1/20 0.34
CA2 P00918 1/20 0.34
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
HDAC3 O15379 3/20 0.31
FFAR3 O14843 2/20 0.31
HDAC8 Q9BY41 2/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19821408 0.89 ALDH1A1 (0.50) HDAC1HDAC2HDAC6CA14CA12
SCHEMBL21470872 0.87 HDAC6 (0.50) HDAC1HDAC2HDAC6ALDH1A1CES2
SCHEMBL23904398 0.83 HDAC6 (0.41) HDAC1HDAC2HDAC6CA14CA12
SCHEMBL28595621 0.82 PHF8 (0.45) HDAC1HDAC2HDAC6CA14NFKB1
SCHEMBL17277202 0.82 HDAC6 (0.41) HDAC1HDAC2HDAC6CA14NFKB1
SCHEMBL14313313 0.81 HDAC6 (0.37) HDAC1HDAC2HDAC6CA14CA12
SCHEMBL21952203 0.79 HDAC6 (0.46) HDAC1HDAC2HDAC6CA14NFKB1
SCHEMBL2246456 0.79 HDAC6 (0.41) HDAC1HDAC2HDAC6CA14CA12
SCHEMBL8737769 0.78 HDAC6 (0.39) HDAC1HDAC2HDAC6CA14CA12
SCHEMBL24737134 0.78 NFKB1 (0.45) HDAC1HDAC2HDAC6CA14CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938249-B2 Anti-amyloid compounds containing benzofurazan TREVENTIS CORPORATION (US) 2018-04-10 US disclosed
US-20170174641-A1 ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN TREVENTIS CORPORATION (US) 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174641-A1 ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN PRNP, PSEN1, APP HDAC1 1221/4885HDAC2 2588/4885HDAC6 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.